A new drug from Novo Nordisk, Semaglutide, was tested in a head-to-head comparison with Eli Lilly’s Trulicity. Both medications belong to a class of drugs called GLP-1 agonists. This class of drug offers many benefits to patients with type 2 diabetes, as they can lower blood glucose while minimizing the chances of hypoglycemic events. A major study comparing these two drugs, called SUSTAIN-7, showed semaglutide performed more effectively for reducing blood glucose and aiding weight loss. Read more